Published on Friday, March 20, 2026 by Chittorgarh.com Team
Issue opens Mar 24, 2026 | Closes Mar 27, 2026 | Listing expected Apr 2, 2026
Key Highlights
For most Indian pharmaceutical companies, entry into regulated markets is a gradual and often time-intensive process. Sai Parenteral’s Limited took a more direct route—acquiring Australia-based Noumed, marking a significant milestone in its global journey.
Anil KK, Chairman & Managing Director, Sai Parenteral’s Limited, said:
“The Noumed acquisition marks an important milestone in our global expansion strategy. By combining Noumed’s capabilities with our manufacturing strengths, we have unlocking synergies across the value chain.”
This is not just another acquisition. It represents a reverse integration—where an Indian pharmaceutical company acquired a regulated-market platform with established market access, product registrations, and customer relationships. In an industry where approvals and distribution networks can take years to build, this provides an immediate and scalable foothold into the $2.5 billion Australian and New Zealand market.
Its subsidiary, Noumed, brings an established presence across Australia and New Zealand, along with long-term supply agreements that provide revenue visibility and customer access from day one. It also adds a large portfolio of TGA-approved dossiers, enabling faster product launches and expansion into other regulated and semi-regulated markets.
Strategically, this creates a strong competitive advantage. India remains the manufacturing backbone—cost-efficient and scalable—while Australia provides direct access to regulated markets. The under-construction manufacturing facility in Adelaide further strengthens this positioning, allowing the Company to manufacture closer to end markets where required.
At a broader level, the acquisition reflects the changing profile of the company. Rather than exporting into global markets, the Company has embedded itself within them.
Today, the Company has scaled to a proforma revenue base of ₹508 crore in FY25 (₹305 crore in H1 FY26), including ₹368 crore from CDMO, and serves customers across Australia, New Zealand, Southeast Asia, the Middle East and Africa.
Sai Parenteral’s ₹409 croreIPO is open from March 24 to March 27. The issue size is ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS from non-promoter shareholders. Sai Parenteral’s IPO Details.
The company is backed by marquee investors including Samarsh Capital (backed by Mr. Mohandas Pai), Dr. B. Bhaskara Rao (MD, KIMS Hospitals), Blue Lotus Capital, Polycab promoters, and Gruhas Proptech (backed by Mr. Nikhil Kamath and Mr. Abhijeet Pai). Read More.
Noumed Unit (Australia)
